Literature DB >> 8120278

Classical pathway complement activation in Kawasaki syndrome.

T Kohsaka1, J Abe, T Asahina, N Kobayashi.   

Abstract

In this study the complement breakdown products C3d, C4d, Bb and membrane attack complex were measured in plasma of patients with Kawasaki syndrome. The results suggested strong activation of the classical activation pathway. However, there was no significant decrease in hemolytic titer or in the concentrations of the intact proteins C3, C4, and B. The relationship between the serum concentrations of cytokines and complement components was examined; increased interleukin-6 concentration on the fifth day after the onset of fever was found to correlate well with the C3 and B concentrations in serum obtained 5 days later. We conclude that complement activation occurred in Kawasaki syndrome via the classical pathway but that the inflammatory reaction was accompanied by increased production of complement components. As a result, there was increased formation of activation products without changes in the serum complement levels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8120278     DOI: 10.1016/0091-6749(94)90362-x

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

1.  Early decreased plasma levels of factor B and C5a are important biomarkers in children with Kawasaki disease.

Authors:  Qing-Mei Zou; Xiao-Hui Li; Rui-Xia Song; Nan-Ping Xu; Ting Zhang; Ming-Ming Zhang; Yao Lin; Lin Shi; Jin Fu; Xiao-Dai Cui
Journal:  Pediatr Res       Date:  2015-05-04       Impact factor: 3.756

2.  Staphylococcus aureus isolates from patients with Kawasaki disease express high levels of protein A.

Authors:  E R Wann; A P Fehringer; Y V Ezepchuk; P M Schlievert; P Bina; R F Reiser; M M Höök; D Y Leung
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 3.  Clinical utility of complement assessment.

Authors:  A E Ahmed; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

Review 4.  Immunoglobulin in the control of complement action.

Authors:  M M Frank; V D Miletic; H Jiang
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

5.  Does the Lectin Complement Pathway Link Kawasaki Disease and SARS-CoV-2?

Authors:  Anastasia Polycarpou; Sofia Grigoriadou; Linda Klavinskis; Steven Sacks
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

Review 6.  Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison.

Authors:  Chetan Sharma; Madhusudan Ganigara; Caroline Galeotti; Joseph Burns; Fernando M Berganza; Denise A Hayes; Davinder Singh-Grewal; Suman Bharath; Sujata Sajjan; Jagadeesh Bayry
Journal:  Nat Rev Rheumatol       Date:  2021-10-29       Impact factor: 20.543

7.  A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease.

Authors:  David Burgner; Sonia Davila; Willemijn B Breunis; Sarah B Ng; Yi Li; Carine Bonnard; Ling Ling; Victoria J Wright; Anbupalam Thalamuthu; Miranda Odam; Chisato Shimizu; Jane C Burns; Michael Levin; Taco W Kuijpers; Martin L Hibberd
Journal:  PLoS Genet       Date:  2009-01-09       Impact factor: 5.917

Review 8.  Vasculitides and the Complement System: a Comprehensive Review.

Authors:  Maria Sole Chimenti; Eleonora Ballanti; Paola Triggianese; Roberto Perricone
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 10.817

Review 9.  C1 esterase inhibitor and the contact system in COVID-19.

Authors:  Timothy M Thomson; Emily Toscano-Guerra; Ernesto Casis; Rosanna Paciucci
Journal:  Br J Haematol       Date:  2020-07-28       Impact factor: 8.615

Review 10.  Identification of key signaling pathways induced by SARS-CoV2 that underlie thrombosis and vascular injury in COVID-19 patients.

Authors:  Anthony J Maxwell; Jiahui Ding; Yuan You; Zhong Dong; Hussein Chehade; Ayesha Alvero; Yechiel Mor; Sorin Draghici; Gil Mor
Journal:  J Leukoc Biol       Date:  2020-11-26       Impact factor: 6.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.